28319-77-9
CAS 28319-77-9
28319-77-9 (CAS 28319-77-9) is a pharmaceutical compound with 2 bioactivity targets and 35 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 30000 nM | 72 | - |
| - | Potency | 54288.5 nM | 6 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 28319-77-9 used for in pharmaceutical contexts?
28319-77-9 (CAS 28319-77-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 28319-77-9?
28319-77-9 has 35 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Amyloid related imaging abnormality-oedema/effusion, Condition aggravated, Confusional state, Diarrhoea, Dry eye. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 28319-77-9 also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Glycerophosphocholine with EU status "permitted".
What clinical phase is 28319-77-9 in?
No phase 1-4 clinical development badge is rendered for 28319-77-9 because the matched compound identifier rows do not contain a max-phase value.